Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
A study looking at pazopanib after chemotherapy in people with advanced non small cell lung cancer (MAPPING - EORTC 08092)
This study looked at pazopanib after chemotherapy for non small cell lung cancer that had spread. This study was supported by Cancer Research UK.
More about this trial
If you have advanced non small cell lung cancer, you may have chemotherapy to help control symptoms and improve your quality of life. Doctors are also looking into controlling the cancer for longer by giving regular doses of a particular drug as a follow up to the main treatment. This is called maintenance treatment.
Pazopanib is a type of biological therapy. It is a cancer growth blocker. It stops signals that cancers use to divide and grow. We know from research that it has helped lung cancers to shrink when given before surgery.
This study looked at having pazopanib after chemotherapy in people who have advanced non small cell lung cancer.
The aim of the study was to find out if pazopanib can control the cancer for longer after chemotherapy.
Summary of results
The trial team found that having pazopanib after chemotherapy wasn’t a useful treatment for people with advanced non small lung cancer.
The people taking part were put into 1 of 2 groups at random.
- 50 people had pazopanib
- 52 people had the dummy drug (
The researchers looked at the early results of the first 102 people who took part. They looked at the average length of time people lived without any signs of their disease getting worse. Researchers call this progression free survival. They found that on average, this was
- Just over 4 months in the people who had pazopanib
- Just over 3 months in the people who had the dummy drug.
The research team had planned to recruit more people but based on these results, the trial team found that the treatment hadn’t worked as well as they had hoped. They decided it was best not to recruit any more people.
The main side effects of pazopanib were mild and included
- High blood pressure
- A drop in the number of
white blood cells
- A raised level of an
enzymein the liver called ALT
The trial team concluded that having pazopanib after chemotherapy didn’t control the cancer for longer. They say that pazopanib couldn’t be looked at in future trials for this group of people without looking at
We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Mary O'Brien
Cancer Research UK
European Organisation for Research and Treatment of Cancer (EORTC)
NIHR Clinical Research Network: Cancer
This is Cancer Research UK trial number CRUKE/11/026